Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Intervention:   Drug: Chidamide Sponsor:   Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Intervention:   Drug: Chidamide Sponsor:   Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Intervention:   Drug: Chidamide Sponsor:   Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma Intervention:   Drug: Chidamide Sponsor:   Great Novel Therapeutics Biotech& Medicals Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Conditions:   nk/T-cell Lymphoma;   Newly Diagnosed;   Advanced Lymphoma Intervention:   Drug: XPO1 inhibitor Sponsor:   Chinese PLA General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 27, 2023 Category: Research Source Type: clinical trials